Table 3

Summary of lymphoma/lymphoproliferative disorder in phase II, III and LTE studies

HistologyEBV statusDemographicsOnset (days)Tofacitinib dose*Location
Large B cell lymphomaNegative78-year-old white female8185 mg twice daily+MTXCentral nervous system
Lymphoma c/w Hodgkin'sPositive51-year-old Asian female2275 mg twice dailyAbdominal lymph nodes
Low-grade B cell lymphomaIgG: ± and non-specific EBNA positive47-year-old
Asian female		22010 mg twice daily+MTXThymus
Large B cell lymphomaEBER positive in rare, scattered mononuclear cells69-year-old white female64210 mg twice daily+MTXLeft breast, mediastinum and left axillary area
Large B cell lymphoma, Burkitt-likeEBER positive in small focus of cells65-year-old
white male		14910 mg twice dailyRight submandibular gland—right neck
Small B cell lymphocytic lymphoma (mantle cell)Negative61-year-old
white female		659
457		5 mg twice daily, 10 mg twice daily†Tonsil
Non-Hodgkin's lymphoma (DCL lymphoproliferative disorder)Negative47-year-old
white female		62510 mg twice daily+MTXSalivary gland
Low-grade non-Hodgkin's B cell lymphoma (CT guided lung biopsy)N/A (no EBV report)65-year-old
white female		16215 mg twice daily+MTXLung
T cell chronic lymphocytic leukaemiaNegative63-year-old
white male		4495 mg twice dailyHaematological
Non-Hodgkin's lymphomaN/A (no EBV report)71-year-old
white female		7235 mg twice dailyGeneralised non-Hodgkin's lymphoma affecting bifurcational, para-aortic, peripancreatic and mesenteric lymph nodes, spleen and body of L3

  • See online supplementary appendix for more details of the lymphoma cases.

  • *Randomised treatment assignment.

  • †Patient was receiving 5 mg twice daily at time of event.

  • DCL, donor cell leukaemia; EBER, Epstein–Barr encoded ribonucleic acid; EBNA, Epstein–Barr nuclear antigen; EBV, Epstein-Barr virus; IgG, immunoglobulin G; LTE, long-term extension; MTX, methotrexate; N/A, not available.